Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.

por Specht, L., Nordentoft, A. M., Cold, S., Clausen, N. T., Nissen, N. I.
Publicado 1987

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

por Gimsing, P, Hjertner, Ø, Abildgaard, N, Andersen, N F, Dahl, T G, Gregersen, H, Klausen, T W, Mellqvist, U-H, Linder, O, Lindås, R, Tøffner Clausen, N, Lenhoff, S
Publicado 2015

Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia

por Hjalgrim, L L, Madsen, H O, Melbye, M, Jørgensen, P, Christiansen, M, Andersen, M T, Pallisgaard, N, Hokland, P, Clausen, N, Ryder, L P, Schmiegelow, K, Hjalgrim, H
Publicado 2002